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Patients with myeloproliferative neoplasms (MPNs) frequently progress to bone marrow
failure or acute myeloid leukemia (AML), and mutations in epigenetic regulators such as the
metabolic enzyme isocitrate dehydrogenase (IDH) are associated with poor outcomes.
Here, we showed that combined expression of Jak2V617F and mutant IDH1R132H or
Idh2R140Q induces MPN progression, alters stem/progenitor cell function, and impairs
differentiation in mice. Jak2V617F Idh2R140Q–mutant MPNs were sensitive to small-molecule
inhibition of IDH. Combined inhibition of JAK2 and IDH2 normalized the stem and
progenitor cell compartments in the murine model and reduced disease burden to a greater
extent than was seen with JAK inhibition alone. In addition, combined JAK2 and IDH2
inhibitor treatment also reversed aberrant gene expression in MPN stem cells and reversed
the metabolite perturbations induced by concurrent JAK2 and IDH2 mutations. Combined
JAK2 and IDH2 inhibitor therapy also showed cooperative efficacy in cells from MPN
patients with both JAK2mut and IDH2mut mutations. Taken together, these data suggest that
combined JAK and IDH inhibition may offer a therapeutic advantage in this high-risk MPN
subtype.
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Introduction
Myeloproliferative neoplasms (MPNs) are clonal myeloid malig-
nancies characterized by somatic mutations acquired in hema-
topoietic stem/progenitor cells, which drive the expansion of 
1 or more myeloid lineages. Although patients with MPN can 
live with their disease for years, a subset of these patients prog-
ress to bone marrow failure or acute myeloid leukemia (AML), 
which are associated with poor clinical outcomes (1–4). Of note, 
patients with accelerated or transformed disease do not respond 
to conventional antileukemic therapies, including cytotoxic 
chemotherapy (1). As such, there is a need to identify biological 
features that drive MPN progression and to identify novel ther-
apeutic targets in patients with high-risk or transformed MPN.
Gene discovery studies have underscored the pathogenic rel-
evance of JAK/STAT activation in chronic MPNs, including muta-
tions in JAK2 (5), MPL (6), and CALR (7, 8). However, the genetic 
and epigenetic events that drive progression and induce adverse 
outcomes have not been fully delineated. Previous studies have 
identified recurrent somatic mutations in epigenetic regulators 
in patients whose disease has transformed from MPN to AML, 
including mutations in isocitrate dehydrogenase 1 (IDH1), IDH2, 
and TET2 (9, 10). These studies are underscored by candidate 
gene studies in patients with chronic MPN, which have shown 
that mutations in epigenetic regulators are associated with poor 
overall survival (11, 12). Of note, patients with concurrent JAK2 
and IDH1/2 mutations have shorter leukemia-free survival (11), 
suggesting that comutations in JAK2 and in IDH1/2 can promote 
MPN progression and transformation.
There is a need to elucidate how mutations in epigenetic regu-
lators cooperate with JAK/STAT pathway-activating mutant alleles 
to promote transformation, with the hope that these insights will 
lead to the development of novel therapeutic approaches for 
this high-risk MPN subtype. Previous studies have shown that 
Jak2V617F-mutant disease is initiated and propagated in the long-
term hematopoietic stem cell (LT-HSC) (13), and coexpression of 
the Jak2V617F allele with loss of Tet2 manifests a more severe MPN 
phenotype (14). Furthermore, we and others have shown that the 
Flt3ITD allele can cooperate with IDH2 gain of function or with 
loss of Tet2 function to induce AML and that the resultant AML 
is initiated and maintained by the multipotent progenitor (MPP) 
cell population (15, 16). The neomorphic ability of mutant IDH to 
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mg, respectively; Figure 1, B and F), which was similar to what 
we observed in the Jak2-mutant controls. IDH1R132H and Idh2R140Q 
mice had elevated serum levels of 2HG (Figure 1, C and G), 
and 2HG levels were higher in mice with concurrent IDH1R132H 
and Jak2V617F mutations compared with mice with the IDH1R132H 
mutation alone (P = 0.0024), suggesting that Jak2 and IDH1 
mutations interact to promote higher 2HG levels (interaction 
P = 0.0375; Figure 1C) through either increased 2HG produc-
tion or higher IDH-mutant cell burden. Expression of mutant 
IDH1 or Idh2 in concert with Jak2V617F resulted in disruption of the 
splenic architecture beyond that observed in Jak2V617F mice, 
including the expansion of blast-like cells with open chroma-
tin and large nucleoli in JAK2/IDH-mutant mice, which was not 
observed in Jak2V617F mice. We found that JAK2/IDH-mutant 
megakaryocytes had increased expression of CD34 by IHC com-
pared with platelet progenitors in Jak2V617F mice, which was con-
sistent with impaired megakaryocytic differentiation (Figure 1, D 
and H). Expression of IDH1R132H in concert with Jak2V617F resulted 
in an overall survival similar to that of mice with expression of 
Jak2V617F alone (median survival, 156 and 359 days, respectively; 
NS), but lower than that of IDH1R132H-mutant and WT mice (medi-
an survival was undefined in an 800-day period; P < 0.0001; 
Figure 1I). Mice transplanted with Jak2V617F/IDH1R132H-mutant 
cells showed significantly reduced survival compared with recip-
ients transplanted with Jak2-mutant cells (median survival of 
206 and 274 days, respectively; P = 0.0480; Figure 1J). Of note, 
previous studies showed that expression of Idh2R140Q was indica-
tive of survival rates that were similar to those observed with our 
IDH1R132H  models (28). These data indicate that concurrent JAK2 
and IDH1/2 mutations cooperate to drive a lethal, transplantable 
MPN with impaired differentiation in vivo.
JAK2/IDH-mutant MPN initiates and propagates disease from 
the LT-HSC compartment. Given that the MPN driven by concur-
rent JAK2/IDH mutations had more efficient disease transplan-
tation, we next sought to define which stem/progenitor cell pop-
ulations could propagate the disease. In competitive transplants 
comparing combined mutant marrow with WT CD45.1+ marrow, 
we found that Idh2R140Q-mutant bone marrow cells were able to 
out-compete WT cells, and the resultant increase in self-renewal 
induced by mutant Idh2 was maintained in cells with concurrent 
Idh2R140Q and Jak2V617F mutations (Figure 2A). Transplant recip-
ients had a phenotype similar to that of primary mice, including 
polycythemia and thrombocytosis. Notably, we observed greater 
leukocytosis in mice engrafted with Idh2R140Q Jak2V617F marrow 
compared with mice transplanted with Jak2V617F-mutant cells (Sup-
plemental Figure 1A; supplemental material available online with 
this article; https://doi.org/10.1172/JCI94516DS1).
Because previous studies have suggested that hematopoietic 
malignancies induced by mutant IDH and Jak2 propagate through 
cells derived from different stem cell compartments (13, 15, 16), 
we sought to explore the cell population that could propagate 
JAK2/IDH-mutant disease. IDH1R132H and Jak2V617F bone marrow 
cells were sorted into LSK (Lin–CD117/c-Kit+Sca1+), LT-HSC (LSK 
CD48–CD150+), and MPP (LSK CD48+CD150–) (Supplemental 
Figure 1B) populations and transplanted into congenic recipi-
ent mice. We assessed disease chimerism and peripheral blood 
counts in the recipient mice and found that mice transplanted with 
produce 2-hydroxyglutarate (2HG) (17, 18), a compound with epi-
genetic effects (19) on myeloid phenotype (20), underscores the 
importance of understanding the role of IDH in these diseases.
Models of combined IDH1/2 and JAK2 mutations provide a 
unique opportunity to explore the efficacy of combined targeted 
therapy against 2 gain-of-function disease alleles in the same leu-
kemic clone. Previous studies have shown that JAK2 inhibitors can 
ameliorate symptoms and reduce spleen size in chronic MPN (21), 
and JAK inhibitor monotherapy can induce transient responses in 
patients with post-MPN AML (22). Preclinical studies with IDH 
inhibitors have been shown to inhibit mutant IDH1/2 function in 
vitro and in vivo and to induce responses in preclinical models, at 
least in part through induction of differentiation (23–25). IDH2 
inhibitors are currently in clinical trials for patients with de novo 
AML, and early-phase clinical data have shown that these agents 
demonstrate efficacy with modest toxicity (26). We therefore sought 
to establish and characterize murine models of accelerated-phase 
MPN with concomitant JAK/STAT activation and IDH mutations to 
identify the disease mechanism and test novel mechanism-based 
combination therapies.
Results
JAK2V617F and neomorphic IDH1/IDH2 mutations cooperate in vivo 
to drive progressive MPN. In order to assess whether IDH and JAK2 
mutations cooperate to transform hematopoietic stem/progeni-
tor cells, we crossed mice with conditional IDH1R132H or Idh2R140Q 
alleles (encoding human IDH1 and murine Idh2 mutations, 
respectively) with mice with a previously described Jak2V617F (13) 
allele, and then used the inducible Mx1-Cre (27) allele to induce 
expression of these alleles in hematopoietic cells. Expression of 
IDH1R132H or Idh2R140Q in concert with Jak2V617F resulted in a fully 
penetrant, lethal disease. In timed sacrifices at approximately 
6 months of age, mice with combined mutations of IDH1R132H or 
Idh2R140Q and Jak2V617F showed polycythemia (mean hematocrit 
levels of 59% and 65%, respectively), leukocytosis (mean leuko-
cyte counts of 23.78 K/μl and 16.22 K/μl, respectively;  1, A and 
E), and splenomegaly (spleen weights of 574.4 mg and 690.7 
Figure 1. Combined Jak2/IDH-mutant mice have lethal MPN with preleu-
kemic features. (A) Hematocrit levels and leukocyte counts in peripheral 
blood, (B) spleen weights, (C) 2HG levels in plasma, and (D) representative 
histology images for CD34 immunohistochemical stains of bone marrow 
and H&E stains of splenic tissue from primary IDH1R132H Jak2V617F Mx1-Cre 
mice sacrificed at approximately 6 months of age (n = 5/group). (E) Hema-
tocrit levels and leukocyte counts in peripheral blood, (F) spleen weights, 
(G) 2HG levels in plasma, and (H) representative histology images for 
CD34 immunohistochemical stains of bone marrow, Wright-Giemsa stains 
of bone marrow cytospins, and H&E stains of splenic tissue from primary 
Idh2R140Q Jak2V617F Mx1-Cre mice sacrificed at approximately 6 months of 
age (n = 4–5/group). (I) Kaplan-Meier survival curve for primary IDH1R132H 
Jak2V617F Mx1-Cre mice following recombination. (J) Kaplan-Meier survival 
curve for secondary-transplant mice following injection of IDH1R132H 
Jak2V617F Mx1-Cre bone marrow. Scale bars: 200 μm. Multiple comparisons 
were performed using an ordinary 1-way ANOVA with Tukey’s correction 
for post-hoc comparisons and multiplicity-corrected P values. Compar-
isons of survival were performed using the log-rank (Mantel-Cox) test. 
Statistical interaction calculated for influence of Jak2 mutation status 
and IDH1 mutation status combined using 2-way ANOVA. *P < 0.05,  
**P < 0.01, ***P < 0.001, and ****P < 0.0001 by 2-way ANOVA. JAKmt, 
JAK-mutant; IDHmt, IDH-mutant; JAKmt/IDHmt, JAK/IDH-mutant.
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with an increase in more primitive stem/progenitor cells and a 
decrease in mature megakaryocyte/erythroid populations.
Combined JAK2/IDH2 inhibition shows increased efficacy in 
JAK2/IDH2-mutant MPN. Given that MPN patients with con-
current JAK2 and IDH mutations are at high risk for disease pro-
gression and have adverse clinical outcomes, we tested whether 
JAK2 inhibition, IDH2 inhibition, or combined JAK2/IDH2 inhi-
bition would show efficacy in treating Jak2/Idh2-mutant MPN. 
We engrafted mice with equal ratios of CD45.2 Jak2/Idh2-mutant 
cells and CD45.1 WT cells, and after the recipient mice developed 
MPN, they were treated with vehicle, the IDH2 inhibitor AG221, 
and/or the JAK kinase inhibitor ruxolitinib (INC18424). We 
observed no evidence of synergistic or additive toxicity with com-
bination therapy, and ruxolitinib therapy did not increase AG221 
levels. Serum 2HG levels in mice engrafted with Idh2R140Q Jak2V617F–
mutant cells (mean, 1,874 ng/ml) were reduced with oral AG221 
therapy at doses between 40 and 100 mg/kg given as monother-
apy (mean, 744.4; P < 0.0001) or in combination with ruxolitinib 
(mean, 562.6 ng/ml; P < 0.0001), consistent with target inhibition 
(Figure 3A). Interestingly, ruxolitinib monotherapy also modestly 
reduced serum 2HG levels (mean, 1,233 ng/ml; P = 0.0016; Figure 
3A). Splenomegaly in diseased mice (mean vehicle-treated spleen 
weight, 289.1 mg) was reduced by AG221 monotherapy (188.3 mg; 
P = 0.0040) or ruxolitinib monotherapy (101.3 mg; P < 0.0001), 
but splenomegaly resolved completely with combined thera-
py (59.53 mg; P < 0.0001; Figure 3B). Combined therapy with 
AG221 and ruxolitinib also normalized polycythemia (hematocrit 
levels of 58.7% vs. 37.61%; P = 0.0028) and leukocytosis (leuko-
cyte counts of 11.62 K/μl vs. 3.111 K/μl; P = 0.0069) to an extent 
beyond that observed with either agent alone (Figure 3C). Total 
LSK cell numbers in the bone marrow of double-mutant mice 
(mean for treatment with vehicle, 57.19 × 103 cells) was reduced 
by AG221 monotherapy (36.43 × 103 cells; NS), ruxolitinib mono-
therapy (20.73 × 103 cells; P = 0.0266), or combined treatment 
(14.42 × 103 cells; P = 0.0090); a similar reduction in stem/pro-
genitor cells was observed in LT-HSCs, short-term hematopoietic 
stem cell (ST-HSC ) (LSK CD48+CD150–), and MPPs (Figure 3D 
and Supplemental Figure 1H). Combined treatment reduced total 
MP numbers in the bone marrow of double-mutant mice (mean 
for treatment with vehicle, 2.46 × 106 vs. 0.8863 × 106) to an extent 
greater than that seen with either agent alone, and this reduction 
was observed in all measured subpopulations including CMPs, 
GMPs, and megakaryocyte-erythroid progenitors (MEPs) (Figure 
3E and Supplemental Figure 1I).
We also found that the expansion of erythrocyte progenitors 
was reduced with either ruxolitinib or AG221 monotherapy or with 
combined therapy. These included pre–CFU-E (mean for treatment 
with vehicle, 0.5189% vs. AG221, 0.1913% [P = 0.0051] vs. ruxoli-
tinib, 0.1103% [P = 0.0005] vs. combined therapy, 0.09978% [P 
= 0.0006]); CFU-E (mean for treatment with vehicle, 1.621 vs. AG 
0.8251 [P = NS] vs. ruxolitinib, 0.5553 [P = 0.0105] vs. combination 
therapy, 0.5868 [P = 0.0180]); and pre-erythrocytes (mean for treat-
ment with vehicle, 0.1757 vs. AG221, 0.03906 [P = 0.0005] vs. rux-
olitinib, 0.08063 [P = 0.0149] vs. combination therapy, 0.02943 [P 
= 0.0003]) (Figure 3F). Treatment with either monotherapy or com-
bined therapy reduced pre-MegE populations (mean for treatment 
with vehicle, 0.1757 vs. AG221, 0.03906 [P = 0.0005] vs. ruxolitinib, 
LT-HSCs, but not MPPs, had evidence of long-term engraftment 
and myeloproliferation (Figure 2B). LT-HSC–transplanted recipi-
ents developed a lethal MPN consistent with efficient propagation 
of the disease from the stem cell compartment (Supplemental 
Figure 1C). These data demonstrate that JAK2/IDH-mutant MPN 
is initiated and propagated in LT-HSCs, in contrast to IDH- and 
Tet2-mutant AML models, in which leukemic stem cell capacity is 
maintained in the MPP cell population.
We next assessed the relative number of stem/progenitor 
cells in JAK2/IDH-mutant mice and found that total LSK cell 
numbers had expanded, with an increase in all hematopoiet-
ic stem and progenitor cell compartments compared with WT 
and IDH single mutants (Figure 2C and Supplemental Figure 1, 
D and E). Concurrent JAK2/IDH mutations drove an increase 
in myeloid progenitors (MPs) (Lin–Sca+c-Kit–), including an 
increase in common myeloid progenitors (CMPs) (Lin–Sca+ 
c-Kit–CD16/32–CD34+; Figure 2G, Supplemental Figure 1, F and 
G). We found that the proportion of myeloid (Mac1+B220–) cells 
that expressed c-Kit was increased in double mutants compared 
with IDH-only (P = 0.0002) and JAK2-only (P = 0.0150) single- 
mutant and nonmutant (P = 0.0008) mice (Figure 2E). To 
explore this further, we examined more granular aspects of the 
myeloid lineage. Pre-megakaryocyte (pre-MegE) populations 
(Lin–c-Kit+Sca1–CD41–CD16/32–CD150+CD105–) were signifi-
cantly reduced in Idh2R140Q Jak2V617F combined mutants com-
pared with Jak2V617F mutants alone, while megakaryocyte pro-
genitors (MkPs) (Lin–c-Kit+Sca1–CD150+CD41+) were expanded 
in Jak2V617F mice, regardless of IDH status (Figure 2F). With 
respect to erythroid progenitors, concurrent JAK2 and IDH2 
mutations resulted in a reduction in CFU erythrocytes (CFU-E) 
(Lin – c-Kit +S ca1 –CD41 –CD16/3 2 –CD150 –CD105 +Ter1 19 –) 
and an increase in pre-erythrocytes (Lin–c-Kit+Sca1–CD41–
CD16/32–CD150–CD105+Ter119+) (Figure 2G). In contrast, pre– 
granulocyte-macrophage progenitors (pre-GMPs) (Lin–c-Kit+ 
Sca1–CD41–CD16/32–CD150–CD105 –) were reduced, while 
granulocyte-macrophage progenitors (GMPs) (Lin–c-Kit+Sca1–
CD41–CD16/32+CD150–) were proportionally expanded (Figure 
2H). These data indicate that combined mutant MPN shows per-
turbations in stem, progenitor, and precursor cell populations, 
Figure 2. Combined mutant mice have expanded pathological stem 
and progenitor cell populations. (A) Peripheral blood donor chimerism 
of competitive transplants with Idh2R140Q Jak2V617F bone marrow over 
time (n = 5/group) and at 12 weeks (n = 5–50/group). (B) Peripheral 
blood chimerism, hematocrit levels, and platelet counts in recipients 
of bone marrow sorted for MPP or LT-HSC LSK populations, 15 weeks 
after injection (n = 5/group). (C) Total number of LSK cells and (D) total 
number of myeloprogenitor cells in bone marrow from primary Idh2R140Q 
Jak2V617F mice and controls according to stem cell/progenitor compart-
ment as measured by FACS (n = 4–5/group). (E) Stem cell populations 
as measured by FACS in peripheral blood and bone marrow from primary 
Idh2R140Q Jak2V617F mice, expressed as a percentage of lineage-negative 
cells. (F) MkP cell populations, (G) erythrocytic progenitor cell popula-
tions, and (H) granulocytic progenitor cell populations as measured by 
FACS in bone marrow from primary Idh2R140Q Jak2V617F mice, expressed as 
a proportion of lineage-negative cells (n = 4–5/group). Multiple com-
parisons were performed using an ordinary 1-way ANOVA with Tukey’s 
correction for post-hoc comparisons and multiplicity-corrected P values. 
*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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0.08063 [P = 0.0149] vs. combined therapy, 0.02943 [P = 0.0003]), 
with a trend toward a reduction in the expanded MkP populations 
in all treatment groups (Figure 3G). Similarly, combined therapy or 
monotherapy reduced pre-GMP and GMP populations (Figure 3H).
IDH2 inhibition or combined JAK2/IDH2 inhibition reduces 
disease burden in vivo. Since JAK2 inhibitors do not substantively 
reduce allele burden in preclinical models of JAK2-mutant disease 
(29) or in the clinical context (21, 30), we next assessed whether 
Figure 3. Treatment of combined mutant mice 
results in the resolution of disease phenotype. 
(A–H) Disease phenotype in transplant recipients 
of Idh2R140Q Jak2V617F bone marrow treated with 
targeted inhibitors at sacrifice after 4 weeks of 
treatment (n = 7–10/group). (A) 2HG levels in 
plasma, (B) spleen weights, (C) hematocrit levels 
and leukocyte counts, (D) total LSK cells classi-
fied by compartment, (E) total myeloprogenitors 
classified by compartment, (F) erythrocytic pro-
genitors, (G) MkPs, and (H) granulocytic progeni-
tors as measured by FACS. Multiple comparisons 
were performed using an ordinary 1-way ANOVA 
with Tukey’s correction for post-hoc comparisons 
and multiplicity-corrected P values. Paired t tests 
were used to determine 2-tailed significance for 
comparison of results in mice before and after 
treatment. *P < 0.05, **P < 0.01, ***P < 0.001, 
and ****P < 0.0001. Comb, combined; inh, inhibi-
tor; Veh, vehicle.
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IDH2 inhibition, alone or in combination with JAK2 inhibition, 
could reduce disease burden in vivo. We assessed the impact of 
AG221 therapy or AG221-ruxolitinib combined therapy on the pro-
portion of Idh2R140Q Jak2V617F MPN cells (CD45.2+) in recipient mice. 
In comparing allele burden in the peripheral blood from individu-
al mice before and after treatment, we observed that mice treated 
with either AG221 or combined JAK2/IDH2 inhibition showed 
significant reductions in mutant donor chimerism (mean change 
before and after treatment for AG221, –6.291%, P = 0.0411, and 
for combination, –7.547%, P = 0.0225). In contrast, mice treated 
with either ruxolitinib or vehicle showed a significant expansion of 
mutant-derived cell burden (mean change before and after treat-
ment for ruxolitinib, +3.256%, P = 0.0122, and for vehicle, +4.236, 
P = 0.0374) (Figure 4A). Examination of only donor-derived 
(CD45.2+) cells revealed that monotherapy with either inhibitor or 
combined IDH2/JAK2 inhibitor therapy reduced the proportion of 
CD45.2+ LSK cells (Figure 4B), whereas the number of CD45.1+ WT 
stem/progenitor cells was not affected (data not shown), indicating 
a potent, selective effect of AG221 on mutant cells in vivo. Within 
the donor-derived LSK compartment, LSK LT-HSC, ST-HSC, and 
MPP subpopulations returned to WT levels (Figure 4B). Consis-
tent with the effect on stem/progenitor cells, we found that IDH2 
inhibitor monotherapy or combined IDH2/JAK2 inhibitor therapy 
reduced the proportion of CD45.2+ MP populations (Figure 4C) 
without affecting the number of CD45.1+ MPs (data not shown). 
Within the donor-derived MP compartment, subpopulations 
including CMPs, GMPs, and MEPs were also partially normalized 
with either monotherapy or combined therapy (Figure 4C). The 
proportion of CD45.2-mutant erythroid progenitor (CD71+Ter119–) 
cells was normalized with combination therapy, consistent with a 
potent suppression of mutant erythroid progenitors (Figure 4D).
Histologically, treatment with JAK2/IDH2 combination ther-
apy normalized bone marrow and splenic morphology, with a 
reduction in the proportion of myeloid cells and the development 
of bone cortex to normal patterns of dilatation by histopathological 
analysis. Treatment with AG221, but not ruxolitinib, reduced the 
aberrant CD34 expression seen in megakaryocytes, whereas com-
bined treatment eliminated the presence of these cells. We also 
observed that AG221 or AG221-ruxolitinib combination therapy 
eliminated the expansion of splenic blasts observed in untreated 
JAK2/IDH2-mutant MPN (Figure 4E).
Combined JAK2/IDH2 inhibition normalizes aberrant transcrip-
tion in JAK2/IDH2-mutant MPN. Given the role of JAK2 as a tran-
scriptional activator and the ability of mutant IDH to modulate the 
epigenetic state (19, 20), we assessed whether combined JAK2/
IDH2 mutations affected gene expression in vivo and whether this 
was abrogated by combined IDH2/JAK2 inhibition. We harvest-
ed and sorted mutant CD45.2 LSK cells from recipient mice 
en grafted with JAK2/IDH2-mutant cells that were treated with 
vehicle, AG221, ruxolitinib, or combination therapy and compared 
their transcriptional output with each other and with WT cells 
through RNA sequencing (RNA-seq). Idh2R140Q Jak2V617F–mutant 
LSK cells had a distinct gene expression profile compared with 
that of WT LSK cells. This gene expression profile demonstrated 
enrichment in MSigDB Hallmark gene sets related to JAK/STAT 
signaling including IL-6/JAK/STAT3 signaling (q = 0.034; NES = 
1.9) and IFN-γ signaling (q = 0.033; NES = 1.9) gene sets (Figure 
5A). We also observed enrichment in several gene expression sets 
related to metabolism, including mTOR (q = 0.005; NES = 2.4) 
and oxidative phosphorylation (q = 0.0047; NES = 2.3) (Figure 5A). 
Finally, the expression of specific oncogenic signatures such as 
cMYC (q = 0.004; NES = 2.5) was increased in JAK2/IDH2-mutant 
cells. Together, these data suggest that concurrent Idh2R140Q and 
Jak2V617F mutations result in transcriptional alterations.
Inhibitor treatment had an impact on aberrant gene expres-
sion in Idh2R140Q Jak2V617F–mutant LSK cells. We observed a more 
dra matic effect on gene expression with combination JAK2/IDH2 
inhibitor therapy than with either monotherapy, such that LSK 
cells derived from mice receiving combination therapy had clus-
tering most similar to that seen among WT LSK cells in unsuper-
vised analysis (data not shown) and in clustering based on differ-
entially expressed genes between diseased and WT mice (Figure 
5B). The perturbations of these genes in vehicle-treated mice com-
pared with WT mice were consistent with previous data sets pub-
lished on a Tet2–/– Jak2V617F combined model (14) compared with 
WT (data not shown). Further, examination of expression changes 
caused by combined treatment showed a significant reversal of 
expression patterns induced by Jak2/IDH mutations (P < 1 × 10–4 
for both down- and upregulated genes) (Figure 5C). A subset of 
gene expression signatures reversed by combination therapy were 
also reversed in mice treated with AG221 monotherapy, and this 
included both upregulated (P < 1 × 10–4; NES = +1.9) and downreg-
ulated (P < 1 × 10–4; NES = –2.3) genes. The combined treatment 
signature showed significant enrichment of gene signatures that 
were also significantly altered by ruxolitinib monotherapy (down-
regulated only, P < 1 × 10–4, NES = –2.2), indicating an additive 
effect of combined treatment on expression changes relative to 
that induced by each monotherapy.
We further characterized the differentially expressed gene sets 
between each treatment group and WT bone marrow. Mice treated 
with ruxolitinib monotherapy showed loss of enrichment of JAK/
STAT-related gene sets compared with vehicle-treated mice. In the 
case of IL-6/JAK/STAT3, enrichment for the expression of genes 
in this pathway was seen in vehicle-treated mice and in stem cells 
from mice treated with AG221 monotherapy. However, this gene 
expression signature was normalized in stem cells from mice treat-
ed with ruxolitinib monotherapy or combined therapy. Similarly, 
IFN-γ signatures, which were significantly enriched in stem cells 
from mice treated with vehicle or AG221 monotherapy, lost signifi-
cance in animals receiving ruxolitinib monotherapy and were neg-
atively enriched in mice treated with combination therapy (Figure 
5D). In the context of these findings, we identified several classical 
oncogene-related gene sets whose gene expression signatures were 
upregulated in diseased mice and reduced or reversed in treated 
mice, including signatures derived from cMYC, mTOR, and KRAS. 
In each of these oncogenic signatures, significant enrichment was 
present in stem cells from mice treated with vehicle, AG221 mono-
therapy, and ruxolitinib monotherapy, however, these aberrant 
gene expression signatures were normalized by or lost statistical 
significance with combined JAK2/IDH2 inhibitor therapy (Fig-
ure 5E). Together, these data indicate that combined treatment 
restores a WT gene expression pattern in LSK cells.
Given the important role of GATA transcriptional regulators 
in myelofibrosis pathogenesis (31) and in Tet2-mutant AML (15), 
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Figure 4. Treatment of combined mutant mice results in reduced disease chimerism. (A) Paired evaluation of donor chimerism in peripheral blood of 
Idh2R140Q Jak2V617F bone marrow recipients before and after treatment with targeted inhibitors for 4 weeks (n = 7/group). (B–D) Stem cell phenotype within 
the donor (CD45.2+) compartment of Idh2R140Q Jak2V617F bone marrow recipients treated with targeted inhibitors (n = 10/group). (B) Total LSK compartments 
expressed as a proportion of the total lineage-negative gate and as proportions of LSK subcompartments. (C) Total myeloid progenitors expressed as a 
proportion of the total lineage-negative gate and as proportions of LSK subcompartments. (D) Erythroid progenitors expressed as proportions of early-, 
middle-, and late-maturity cells. (E) Representative images of bone marrow morphology with dilatations, CD34 immunohistochemical staining in the bone 
marrow with digital quantification of staining (graph), and splenic cell/blast morphology in Idh2R140Q Jak2V617F bone marrow recipients treated with targeted 
inhibitors. Scale bars: 200 μm. Multiple comparisons were performed using an ordinary 1-way ANOVA with Tukey’s correction for post-hoc comparisons 
and multiplicity-corrected P values. Paired t tests were used to determine 2-tailed significance for comparison of results in mice before and after treat-
ment. *P < 0.05, and **P < 0.01.
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ples from patients with clinically determined MPN and post-MPN 
AML with IDH2R140Q and JAK2V617F mutations (Table 1). This anal-
ysis included 1 patient for whom combined mutant samples were 
available from both the chronic-phase MPN and the time of leuke-
mic transformation (patient 24; Figure 7A). All the patients showed 
a characteristic pattern of colony formation, with an increase in 
colony numbers with IDH inhibitor monotherapy. The presence 
of erythroid burst-forming unit (BFU-E) colonies was consistent 
with the restoration of erythroid differentiation as previously 
described (25), and 3 of the 5 patients also showed IDH2 inhibition– 
associated increases in GM colonies, indicating that myeloid 
differentiation was restored by IDH2 inhibition (Figure 7A). On 
morphological examination, we found that this expansion was 
also associated with the presence of large, well-differentiated col-
onies compared with the control colonies (Figure 7B). FACS anal-
ysis showed that IDH2 inhibitor treatment reduced the surface 
expression of the immature marker c-Kit (also known as CD117) 
(Figure 8A). With respect to differentiation markers, we found 
that most patients’ samples treated with AG221 showed upregu-
lation of either the erythroid marker CD235a (Figure 8B) or the 
myeloid marker CD14, consistent with restored differentiation in 
JAK2/IDH2-mutant MPN and AML cells (Figure 8C). In contrast, 
we observed that JAK inhibitor therapy, alone or in combination 
with IDH2 inhibitor therapy, reduced colony output. Combination 
treatment attenuated the increase in colony numbers seen with 
IDH2 inhibitor monotherapy, while still maintaining the effect of 
IDH2 inhibition on promoting differentiation, as evidenced by a 
reduction in the proportion of c-Kit+ colonies and an increase in 
the proportion of CD235a+ and CD14+ colonies, which was not 
seen with ruxolitinib treatment alone. These data suggest that, 
while JAK2 inhibitor therapy attenuates proliferation, IDH inhib-
itor therapy increases cell numbers by promoting differentiation. 
Therefore, combined JAK and IDH2 inhibitor therapy can have 
cooperative effects through these 2 responses (33).
Discussion
Past studies have underscored the importance of mutations in 
epigenetic regulators in the pathogenesis of myeloid malignancies 
we performed quantitative PCR for Gata1 and Gata2 in donor- 
derived MEPs isolated from vehicle- and inhibitor-treated mice. 
Double-mutant recipients treated with vehicle showed a statistical-
ly significant increase in Gata1 expression compared with expres-
sion in WT controls (3.242-fold elevation; P = 0.0200) (Figure 5F), 
and this increased expression normalized with single and com-
bined inhibitor treatment (32). Gata2 levels showed a trend toward 
increased expression in mice treated with IDH inhibition (Figure 
5F), consistent with results in Tet2-mutant AML (15).
Combined JAK2/IDH2 inhibition has cooperative effects to reverse 
altered metabolism in JAK2/IDH2-mutant MPN. We next inves-
tigated the effect of these treatment regimens on JAK2/IDH2- 
mutant MPN cell metabolism. We used liquid chromatography/
mass spectrometry (LC/MS) to measure metabolites from murine 
bone marrow aspirates after 10 days of treatment with vehicle, 
ruxolitinib or AG221 monotherapy, or combined therapy. We first 
verified that 2HG levels were reduced with IDH inhibitor mono-
therapy (Figure 6A). IDH inhibitor monotherapy also reduced lev-
els of Krebs cycle intermediates including α-ketoglutarate, citrate, 
succinate, fumarate, and malate (P < 0.0252; Figure 6B). 2HG lev-
els were also reduced with ruxolitinib inhibitor monotherapy (Fig-
ure 6A), which is consistent with what we detected in the serum 
of treated mice (Figure 3A). We also found that ruxolitinib mono-
therapy reduced pool sizes of citrate (P = 0.0064), fumarate (P = 
0.0224), and malate (P < 0.0001; Figure 4G). Consistent with our 
observations in serum, mice treated with combined therapy had 
2HG levels similar to those of WT mice (Figure 6A), indicating a 
combined effect of the 2 drugs. We also observed a reduction of 
glutamate levels with ruxolitinib monotherapy (P = 0.0026) and 
combined therapy (P = 0.0049) that was accompanied by a coor-
dinate increase in glutamine, particularly in mice that received 
combination therapy (Figure 6C). These data provide a potential 
point of intersection between the JAK2- and IDH2-mutant path-
ways in the regulation of glutamate and glutamine metabolism.
Inhibition of JAK and mutant IDH shows cooperative efficacy in 
primary MPN samples from patients with JAK2/IDH2 mutations. 
To explore the relevance of these findings to human disease, we 
performed methylcellulose assays on CD34+-enriched blood sam-
Table 1. Clinical characteristics of patients at the time of sample collection
Clinical characteristics at time of sample collection Genetic analysis of primary samples
Sample Age Sex Diagnosis Disease status Treatment Cytogenetics Idh2 Jak2 Dnmt3a Additional mutations
MPN pt 71 71 F Polycythemia vera Stable disease Hydroxyurea, 
anagrelide
Normal karyotype R140Q V617F WT FOXP1-R66fs 
MPN pt 24 72 M Myelofibrosis Newly diagnosed Untreated Not performed R140Q V617F WT  
AML pt 24 74 M Post-MPN AML 
(myelofibrosis)
Newly diagnosed Previously 
ruxolitinib, 
otherwise 
untreated 
Normal karyotype R140Q V617F WT NRAS-G12V
AML pt 91 78 M Post-MPN 
AML (essential 
thrombocythemia) 
Persistent disease Decitabine, 
hydroxyurea
Normal karyotype R140Q V617F R882H TET2-H1077R
AML pt 09 61 M AML Persistent disease Daunorubicin, 
cytarabine
Trisomy Ch2 
hypertetraploidy
R140Q V617F R882H RUNX1-S226delinsTR
pt, patient.
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gesting that there are important differences in how different sig-
naling mutations cooperate with epigenetic regulator mutations to 
induce hematopoietic transformation.
Consistent with this hypothesis, we demonstrate that the MPN 
stem cell capable of propagating JAK2/IDH-mutant disease is 
found in the LT-HSC compartment, as observed in Jak2V617F-driv-
en MPN. By contrast, combined Flt3ITD and Tet2/Idh2-mutant 
leukemia was found to be maintained and propagated by the MPP 
lineage–restricted progenitor population (15, 16). This could be 
due to the observation that JAK2/IDH-mutant disease remains 
an accelerated-phase MPN versus the AML observed in combined 
Flt3ITD- and Tet2/Idh2-mutant disease, such that the leukemic 
stem cell remains in the LT-HSC compartment in chronic-phase 
disease until blast transformation. Alternatively, it is possible that 
the expression of different signaling effectors, such as Jak2 or Flt3, 
differs in different stem/progenitor cell compartments, such that 
oncogenic signaling induced by different kinase alleles promotes 
transformation in different cell types, which then dictates the 
phenotype in concert with mutated epigenetic regulators. Subse-
quent studies, in which different MPN and AML disease alleles are 
expressed in specific stem/progenitor cell populations, alone and 
in concert, are needed to delineate the role of the specific muta-
tions and of the specific cellular compartments in which muta-
tions are acquired in dictating leukemic phenotype and stem cell 
capacity, because these aspects of hematopoietic disease strongly 
affect treatment targeting strategies and effects.
Importantly, we demonstrate that Jak2/IDH-mutant MPN 
is highly sensitive to IDH-mutant inhibition and that combined 
Jak2/IDH-mutant–directed targeted therapy has potent anti-
leukemic effects. Specifically, we found that treatment with the 
IDH2 inhibitor AG221 showed efficacy in Jak2/Idh2-mutant 
MPN, including attenuation of myeloid expansion, reversal of 
stem cell expansion, and a reduction in the mutant allele bur-
den. Combination therapy with AG221 and ruxolitinib showed 
increased efficacy without additive toxicity, with reduced disease 
burden and reversal of aberrant myeloproliferation in vivo. These 
data provide a rationale for combined JAK2/IDH2-targeted inhi-
bition in this high-risk MPN subtype. Additionally, the apparent 
suboptimal response of double-mutant mice to a JAK2 inhibitor 
regimen and the apparent response of double-mutant 2HG lev-
els in serum to single-agent therapy imply a metabolic and gene- 
regulatory cooperativity between the JAK/STAT pathway and the 
mutant IDH–mediated effect.
Consistent with the effects on Jak2/Idh2-mutant–driven MPN 
in vivo, combination therapy reversed the aberrant transcription-
al and metabolic abnormalities in JAK2/IDH2-mutant stem/
progenitor cells. Given the role of mutant IDH enzymes in alter-
ing the epigenetic state and gene regulation, it is not surprising 
that inhibition of mutant IDH function would have a significant 
impact on gene expression in Idh2-mutant stem cells. However, 
the observation that dual inhibition of JAK signaling and mutant 
IDH2 function leads to further normalization of aberrant gene 
expression in JAK2/IDH2-mutant stem/progenitor cells suggests 
that there is interplay between JAK signaling and epigenetic reg-
ulation in driving aberrant gene expression in Jak2/Idh2-mutant 
MPN. JAK2V617F has been implicated directly in epigenetic regu-
lation of histone modifications (37), but the fact that JAK2 inhi-
(34, 35). This includes the neomorphic mutations in IDH1/2 seen 
in AML and MPN, which, through the production of 2HG, can 
alter the function of DNA and histone-modifying enzymes (36). 
Of importance in MPN are the observations that mutations in epi-
genetic regulators are associated with adverse clinical outcomes 
and the specific role of IDH1/2 mutations in promoting MPN 
progression and transformation (9–12, 14, 24, 34, 35). Here, we 
show that JAK2 and IDH concurrent mutations can promote MPN 
progression and that this disease is sensitive to combined JAK2/
IDH-targeted therapy.
Expression of Jak2V617F in concert with Idh2R140Q or IDH1R132H 
in hematopoietic cells resulted in an accelerated MPN phenotype 
with preleukemic features. This disease is characterized by poly-
cythemia and leukocytosis, which were also observed in Jak2V617F 
mice (13). However, expression of mutant IDH1 or IDH2 in con-
cert with Jak2V617F resulted in the expansion of blasts and impaired 
hematopoietic differentiation, which are features of human MPN 
indicative of disease progression and adverse clinical outcome. 
These features suggest that expression of IDH1 or IDH2 in con-
cert with Jak2V617F impairs differentiation and probably contrib-
utes to leukemic transformation, which is consistent with correl-
ative genetic studies showing that the primary effect of IDH1/ 
2 mutations in MPN is that of promoting accelerated progression 
to post-MPN AML. The phenotype we observed here shares some 
similarities with the phenotype reported in Jak2V617F Tet2null mice 
(14) and is consistent with the observation that mutant IDH–medi-
ated production of 2HG inhibits TET2 catalytic function (19). 
However, although concurrent JAK2 and IDH/TET2 mutations 
have been reported with high frequency in post-MPN AML (9), 
the lack of overt acute transformation in mice with these concur-
rent mutations suggests that there are additional genetic and epi-
genetic events that are required to induce the transformation from 
MPN to AML. Importantly, these data are distinct from those of 
recent work showing that mutant Idh2/Tet2 can cooperate with 
Flt3ITD to potently induce a fully penetrant AML phenotype, sug-
Figure 5. Expression in donor-derived (CD45.2+) LSK cells by RNA-seq 
defines the  gene set of combined mutant disease, and treatment erad-
icates this expression profile. (A–E) RNA-seq analysis of donor derived 
(CD45.2+) LSK cells in Idh2R140Q Jak2V617F bone marrow recipients treated with 
targeted inhibitors (n = 3/group). (A) Significantly enriched Hallmark GSEA 
in comparative expression patterns comparing vehicle/diseased mice to 
WT. (B) Clustering of all treated mice depicting comparative phylogeny of 
samples and relative expression of the 100 most significantly differentially 
expressed genes. (C) Examination of genes differentially expressed between 
combined treatment mice and vehicle-treated mice using a gene set defined 
according to genes differentially expressed between WT and vehicle-treated 
mice. (D and E) Calculated normalized enrichment score (NES) values (y axis) 
and FDR (x axis) of curated Hallmark GSEA showing the  level and signifi-
cance of enrichment in each treatment group compared with WT examined 
for enrichment in curated Hallmark GSEA lists related to JAK/STAT signaling. 
Statistically significantly non-zero NES values are depicted in bright colors, 
while nonstatistically significant NES values are depicted in pastel colors. (D) 
Hallmark GSEA highlighting several pathways related to JAK/STAT signaling 
and (E) several oncogenic pathways. (F) Quantitative PCR for Gata1 and 
Gata2 expression performed on sorted MEPs from drug-treated mice. See 
Methods for details on the statistical methods used for the bioinformatics 
analysis in A and C. Multiple comparisons were performed using an ordinary 
1-way ANOVA with Tukey’s correction for post-hoc comparisons and multi-
plicity-corrected P values. *P < 0.05.
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vided by Craig B. Thompson (Memorial Sloan Kettering Cancer Center). 
All mice were maintained on a C57BL/6J background, and the lines were 
backcrossed for 6 generations before use in experiments. Samples for 
experiments were obtained from male and female mice aged 6 months 
to 1.5 years. Upon induction, mice received 5 i.p. injections of polyI:polyC 
(Amersham) of 200 μl of a 1-mg/ml solution. Peripheral blood was col-
lected via cheek bleeding using heparinized microhematocrit capillary 
tubes (Thermo Fisher Scientific). Peripheral blood counts were obtained 
using a HemaVet according to the manufacturer’s instructions. Excision 
2 weeks after induction was confirmed using PCR.
Histology. Pathology was obtained after fixation in 4% parafor-
maldehyde (PFA); blood smears and bone marrow cytospins were 
performed on the day of sacrifice. Sections were stained with H&E or 
Wright Giemsa as appropriate. CD34+ staining was performed using 
CD34 rat monoclonal antibody on a Leica Bond RX using the Bond 
Polymer Refine Detection Kit (catalog DS9800; Leica). The sections 
stained with CD34 (catalog Ab8158; Abcam; diluted 1:50) were pre-
treated using heat-mediated antigen retrieval with citrate, pH6 (cata-
log AR9961; Leica Biosystem Epitope Retrieval 1) for 20 minutes. DAB 
was used as the chromogen. Samples were further counterstained with 
hematoxylin and mounted.
Bone marrow transplantation studies. Dissected femurs and tibi-
ae were isolated. Bone marrow was flushed into PBS plus 2% BSA or 
RPMI plus 10% FCS using a syringe or by centrifugal spinning. Spleens 
were isolated, and single-cell suspensions were made by mechanical 
disruption using glass slides. All harvested cells were passed through 
a 70-mm strainer. RBC were lysed in ammonium chloride–potassium 
bicarbonate lysis buffer for 10 minutes on ice. Cells were transplanted 
via tail-vein injection into lethally irradiated (2 × 5.50 Gy) CD45.1 host 
mice (The Jackson Laboratory). For noncompetitive transplants, 1 × 
106 total cells were transplanted; for competitive transplants including 
bition alone lowered 2HG levels and affected metabolite levels 
in this study raises the possibility that reversing the effect of JAK 
signaling on metabolism may influence epigenetic regulation of 
gene expression. This is plausible, as levels of metabolites other 
than 2HG can influence the methylation status of DNA and his-
tones, both within the Krebs cycle (38) and in metabolic species 
beyond it (39). Future studies are needed to delineate specific 
mechanisms by which constitutive JAK/STAT signaling cooper-
ates with mutant IDH to alter the epigenetic and transcriptional 
state in hematopoietic cells, but combined inhibition of JAK2 and 
IDH2 had a greater impact on reversing aberrant metabolism in 
Jak2/Idh2-mutant cells than could be attributed to inhibition of 
neomorphic IDH2 function alone.
Relevant to patients, the present data suggest an important 
role for neomorphic IDH mutations in promoting disease pro-
gression in concert with activated JAK2 signaling and inform a 
mechanism-based combination therapy approach for this high-risk 
MPN subtype. The results of our in vitro experiments using patients’ 
samples indicate that IDH inhibition expands the population of 
differentiated cells, which is consistent with the findings in current 
trials of the drug in de novo AML (33). Given that MPN patients 
with JAK2/IDH concurrent mutations have a worse prognosis 
than do patients with other MPN subtypes, there is a need for new 
therapeutic options. These data provide a rationale for combined, 
mutant-specific, targeted therapy in this high-risk MPN subtype.
Methods
Transgenic animals. The conditional Jak2V617F mice were previously 
described (13). Conditional transgenic IDH1R132H mice (expressing 
a mutation in the IDH1 gene) were provided by Kwok-Kin Wong 
(Dana-Farber Cancer Institute), and conditional Idh2R140Q mice were pro-
Figure 6. Treatment of combined mutant bone marrow with combined inhibitors perturbs 
pools of metabolic products. (A–C) MS analysis of metabolites from whole–bone marrow 
aspirate cells from treated and WT mice, normalized to leucine levels. (A) 2HG levels, (B) 
citrate, α-ketoglutarate, succinate, fumarate, and malate levels, and (C) glutamate and 
glutamine levels. Multiple comparisons were performed using an ordinary 1-way ANOVA with 
Tukey’s correction for post-hoc comparisons and multiplicity-corrected P values. *P < 0.05, 
**P < 0.01 and ****P < 0.0001.
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exclusion from the analysis. Cells were also stained with antibodies 
specific to c-Kit/CD117 (clone 2B8; BioLegend), Sca-1 (clone D7; Bio-
Legend), FcγRII/III/CD16/32 (clone 2.4G2; eBiosciences), and CD34 
(clone RAM34; eBiosciences) or SLAM/CD150 (clone TC15-12F12.2; 
BioLegend) and CD48 (clone HM48-1; eBioscience). To assess mature 
cell lineages, a combination of antibodies against Mac1, Gr-1, B220, 
CD3, c-Kit/CD117, CD45.1, and CD45.2 was used.
To assess erythroid and megakaryocyte progenitors, we stained 
unlysed tissues with a lineage cocktail consisting of CD4, CD8, B220/
CD45R, Mac1/CD11b, Gr-1, IL7R/CD127 (clone A7R34; BioLegend), 
and CD49b (clone DX5; BioLegend). Antibodies against c-Kit/CD117, 
Sca-1, SLAM/CD150, CD48, FcγRII/III/CD16/32, CD41 (clone 
eBioMWReg30; eBioscience), CD105 (clone MJ7/18; BioLegend), 
CD71 (clone RI7217; BioLegend), and Ter119 were also used and gated 
as previously described (40).
Before cell-of-origin transplantations, sorting was performed on 
bone marrow with enrichment for c-Kit+ cells using CD117 Micro-
Beads (Miltenyi Biotec). For expression analysis, sorting was per-
formed on bone marrow that had been depleted of mature cells using 
a Progenitor Cell Enrichment Kit (STEMCELL Technologies).
Metabolomic analysis. Analysis of serum 2HG was performed 
by extraction with 80% aqueous methanol as previously described 
(41). All extracts were spun at 13,000 rpm at 4°C to remove precip-
itate, dried at room temperature, and stored at –80°C. Metabolite 
levels were determined by ion-paired, reverse-phase LC coupled to 
negative-mode, electrospray triple-quadrupole MS using multiple 
drug studies, 1 × 106 total donor cells were injected into a mixture with 
1 × 106 cells from a congenic CD45.1 donor; for cell-of-origin trans-
plants, the injection number was determined on basis of the lowest 
yield after sorting to inject approximately 100,000 MPPs or 300 
LT-HSCs with 300,000 whole bone marrow cells from a CD45.1 donor.
Therapeutic assays. Approximately 2 months after competitive 
transplantation, peripheral blood analysis was performed with a 
HemaVet and FACS for donor chimerism. Mice were matched using Z 
scores representing hematocrit (HCT) (percentage), WBC (K/μl), donor 
chimerism, and body weight, and mice were randomized within match-
ing groups using a random number generator. Drugs were administered 
twice daily by gavage for 21 to 28 days, unless otherwise indicated. 
Ruxolitinib (a gift of James Bradner, Dana-Farber Cancer Institute) was 
administered at a dose of 60 mg/kg, and AG221 (Agios Pharmaceuti-
cals) was administered at a dose of 100 mg/kg or 40 mg/kg. Final doses 
were administered approximately 1.5 hours before sacrifice.
Flow cytometry and FACS for murine tissues. Cells were stained 
with antibodies in FACS buffer (2% BSA in PBS) for 30 minutes on ice. 
Donor and support chimerism was assessed using antibodies against 
CD45.1 (clone A20; BioLegend) and CD45.2 (clone 104; BioLegend).
For hematopoietic stem and progenitor cell staining, cells were 
stained with a lineage cocktail consisting of CD4 (clone RM4-5; 
BioLegend), CD3 (clone 17A2; BioLegend), B220/CD45R (clone 
RA3-6B2; BioLegend), NK1.1 (clone PK136; BioLegend), Gr-1 (clone 
RB6-8C5; BioLegend), Mac1/CD11b (clone M1/70; BioLegend), and 
Ter119 (catalog 116223; BioLegend) and allowing for mature lineage 
Figure 7. Human IDH2R140Q JAK2V617F MPN and AML samples in methylcellulose respond to IDH inhibitor therapy with a differentiation phenotype by 
morphology. (A) Colony counts of cultured cells classified by colony morphology including GM and BFU-E colonies. Multiple comparisons were performed 
using an ordinary 1-way ANOVA, using Tukey’s correction for post-hoc comparisons and multiplicity-corrected P values. *P < 0.05, **P < 0.01, ***P < 0.001, 
and ****P < 0.0001 by 2-way ANOVA. (B) Representative images of colonies taken during culturing of cells from MPN patient 71. Magnification ×4. Expres-
sion levels of cell-surface markers on cultured cells after therapy as measured by mean fluorescence intensity (MFI) using FACS antibodies: (C) CD117, (D) 
CD235a, (E) CD14.
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Expression analysis. CD45.2+ LSK cells were sorted into ice-cold 
FACS buffer, pelleted, resuspended, and stored in TRIzol (Invitro-
gen/Thermo Fisher Scientific) until extraction of RNA using phenol- 
chlorophorm. The library was produced using SMARTer amplification 
(Clontech Laboratories) to amplify and create the library. Illumina 
sequencing was performed using paired-end 50 bp at 40 × 106 reads 
per sample.
FASTQ files were aligned to mm10 using STAR, version 2.5.1a (43) 
with default parameters. Counts were generated using the Ensembl 
gene model (https://www.ensembl.org/info/genome/genebuild/
genome_annotation.html) and STAR, version 2.5.1a, with the —quant-
Mode parameter. Differential expression analysis was performed 
reactions monitoring, and integrated elution peaks were compared 
with metabolite standard curves for absolute quantification (17).
For central carbon metabolite profiling of flash-frozen bone mar-
row aspirates, polar metabolites were extracted from flash-frozen bone 
marrow aspirates using 5:3:5 ice-cold methanol/water/chloroform on 
ice. Extracts were vortexed for 10 minutes at 4°C and then centrifuged 
for 5 minutes at 4°C at maximum speed on a tabletop centrifuge. Equal 
volumes of the aqueous phase from each sample were removed and 
dried under nitrogen gas and then resuspended for LC/MS analysis, 
and 1 μl of each sample was injected for hydrophilic interaction–LC/MS 
(HILIC-MS analysis) on a Dionex Ultimate 3000 UPLC System coupled 
to a QExactive Orbitrap Mass Spectrometer as previously described (42).
Figure 8. Human IDH2R140Q JAK2V617F MPN and AML samples in methylcellulose respond to IDH inhibitor therapy with a differentiation phenotype by 
cell-surface marker measurement. (A–C) Expression levels of cell-surface markers on cultured cells after therapy as measured by mean fluorescence 
intensity (MFI) using the following FACS antibodies: (A) CD117, (B) CD235a, and (C) CD14. Multiple comparisons were performed using an ordinary 1-way 
ANOVA with Tukey’s correction for post-hoc comparisons and multiplicity-corrected P values. *P < 0.05, **P < 0.01, and ***P < 0.001. P value in A 
obtained by 2-way ANOVA.
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mals and approved by the IACUC of Memorial Sloan Kettering Cancer 
Center. Tissue samples were collected in partnership with the Human 
Oncology Tissue Bank, and all patients provided written informed 
consent. Approval for the use of human samples was obtained from 
the IRB of Memorial Sloan-Kettering Cancer Center.
Data and materials availability. RNA-seq data used in this work 
were deposited in the NCBI’s Gene Expression Omnibus (GEO) data-
base (GEO GSE95771).
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using the Bioconductor DESeq2 package (44) with default parame-
ters. Heatmaps were generated using the CRAN NMF package (45) 
and normalized counts as provided by DESeq2. Gene set enrichment 
analysis (GSEA) (46, 47) was performed using MSigDB Hallmark gene 
sets (http://software.broadinstitute.org/gsea/msigdb/collections.jsp). 
Custom gene sets for JAK2/IDH disease were generated using all 
genes that were significantly differentially expressed, with Benjamini- 
Hochberg–adjusted P values of less than 0.0001.
Quantitative PCR for mRNA. CD45.2+ MEPs were sorted into ice-
cold FACS buffer, pelleted, resuspended, and stored in TRIzol until 
extraction of RNA using phenol-chloroform. The RNA was then used 
as a template for cDNA synthesis using the Verso cDNA Kit (Thermo 
Fisher Scientific). Quantitative real-time PCR reactions were carried 
out using SYBR Green Master Mix (Life Tech) on an Applied Biosci-
ences qPCR cycler. Relative expression was determined by the Δ/ΔCt 
method and normalized to the internal control GAPDH.
Human tissues. Fresh peripheral blood was collected into heparin-
ized collection tubes, and separation of peripheral blood mononuclear 
cells (PBMCs) was performed using hetastarch and a Ficoll gradient 
with subsequent RBC lysis.
Human colony-forming assays. Frozen or fresh PBMCs were 
plated in MethoCult H4435 (STEMCELL Technologies) with penicil-
lin and streptomycin in triplicate wells. Cells from MPN patients were 
plated after enrichment using CD34 Microbeads (Miltenyi Biotec) at 
1,000 cells per well, and cells from AML patients were plated with-
out enrichment at 100,000 cells per well. AG221 and ruxolitinib were 
dissolved into samples at a 400-nM concentration, and DMSO was 
dissolved into the controls.
Flow cytometry for human tissues. To observe erythroid differentiation 
in human tissues, staining was performed with a combination of CD117/
c-Kit (clone YB5.B8; eBioscience), CD34 (clone 581; BioLegend), CD38 
(clone HIT2; BioLegend), CD36 (clone 5-271; BioLegend), CD71 (clone 
OKT9; eBioscience), and CD235a (clone HIR2; eBioscience). To observe 
monocytic and granulocytic differentiation, antibodies against CD117/ 
c-Kit, CD34, CD38, CD15 (clone HI98; eBioscience), CD14 (clone 
HCD14; BioLegend), and CD16 (clone 3G8; BioLegend) were used.
Statistics. Data are presented as the mean ± SEM. GraphPad Prism 
7 software (GraphPad Software) was used to conduct the statistical 
analysis of all data. Multiple comparisons were performed using an 
ordinary 1-way ANOVA with Tukey’s correction for post-hoc compar-
isons and multiplicity-corrected P values. Survival comparisons were 
made using the log-rank (Mantel-Cox) test. Statistical interaction cal-
culated for  combined influence of JAK and IDH mutation or inhibi-
tion status combined was determined using 2-way ANOVA. Paired t 
tests were used to determine 2-tailed significance to compare results 
in mice before and after treatment. A P value of less than 0.05 was 
considered statistically significant.
Study approval. All animal procedures were conducted in accor-
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